SCHEMBL22492260

SCHEMBL22492260

CNC(=O)Oc1cccc(S(=O)(=O)NN)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.47
BCHE P06276 2/20 0.47
MEP1B Q16820 1/20 0.43
ALDH1A1 P00352 5/20 0.42
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
HPGD P15428 2/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
ADAMTS4 O75173 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
KAT6A Q92794 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22492235 0.82 ACHE (0.49) ACHEBCHEMEP1BALDH1A1SMN1; SMN2
SCHEMBL10815679 0.79 ACHE (0.61) ACHEBCHEALDH1A1SMN1; SMN2KDM4E
SCHEMBL421587 0.78 KEAP1 (0.60) MEP1BALDH1A1FLT1FLT4KDR
SCHEMBL11212409 0.77 PGR (0.53) ALDH1A1SMN1; SMN2FFAR4KEAP1NFE2L2
SCHEMBL4266372 0.74 ACHE (0.54) ACHEBCHEALDH1A1SMN1; SMN2KDM4E
Metolcarb SCHEMBL27347183 0.74 LMNA (0.57) ACHEBCHEALDH1A1SMN1; SMN2KDM4E
SCHEMBL3867518 0.74 LMNA (0.53) ACHEMEP1BALDH1A1SMN1; SMN2KDM4E
SCHEMBL148204 0.73 CA2 (0.54) ALDH1A1SMN1; SMN2KDM4ENPC1HPGD
SCHEMBL20264521 0.73 BCHE (0.55) ACHEBCHEALDH1A1SMN1; SMN2KDM4E
Metolcarb SCHEMBL118244 0.73 LMNA (0.65) ACHEBCHEALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. (US) 2023-11-09 US disclosed
US-11685732-B2 MYST family histone acetyltransferase inhibitors Epizyme, Inc. (US) 2023-06-27 US disclosed
US-20220162197-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. 2022-05-26 US disclosed
EP-3716964-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. (US) 2020-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162197-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS EP300, KAT2A, KAT6A ACHE 2874/4885BCHE 2324/4885MEP1B 1980/4885
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS EP300, KAT2A, KAT6A ACHE 2874/4885BCHE 2324/4885MEP1B 1980/4885
US-11685732-B2 MYST family histone acetyltransferase inhibitors EP300, KAT2A, KAT6A ACHE 2874/4885BCHE 2324/4885MEP1B 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.